Commercial-hit files
47
licensing, package, buyer, rights, IP, valuation, or commercial-density records identified
Buyer diligence
BioAtlas diligence is staged, protected, and buyer-specific.
This page is the public front door for strategic review. It explains how a buyer, investor, acquirer, pharma team, biotech partner, institution, or enterprise reviewer can understand the asset estate before requesting protected material.
Public diligence shows categories, boundaries, provenance, and review workflow. It does not expose private vault files, internal app routes, raw datasets, protected commercial terms, admin systems, or acquisition material.
Buyer / market signals
702
clinic, oncology, research, biotech, pharma, enterprise, institution, investor, and acquirer language
Package / bundle signals
1,123
module, package, kit, dataset, engine, API, tier, institutional, and product-family language
Rights / IP signals
27
exclusive, territorial, global, royalty, revenue share, no-AI, no-derivative, and usage-boundary terms
BioAtlas public estate map
Open for exploration. Governed for responsible use.
BioAtlas is staged deliberately: public proof, research provenance, platform engines, commercial packaging, protected diligence, and reviewed access. Each layer shows enough for the right audience without exposing protected routes, data-room material, or internal app surfaces.
01Open
Public proof layer
Readable public pages, safe summaries, route maps, DOI links, and the high-level BioAtlas story.
public pagessafe summariesroute map
02Open
Research provenance
DOI-backed papers, preprints, Zenodo records, grouped research collections, and public provenance.
DOI indexpreprintsresearch collections
03Open
Platform engines
QTOS, Rubik, ECS, oncology, microbiome, cell atlas, systems biology, neuro, and infrastructure families.
engine familiesplatform overviewinvestor proof
04Open
Commercial packaging
Licensing families, dataset access, SaaS/API routes, white-label scope, and AI-rights boundaries.
asset familiesrights architecturebuyer routes
05Open
Protected diligence
Buyer review, data-room categories, staged release, provenance, IP boundaries, and technical diligence.
data-room mapbuyer reviewprotected boundaries
06Open
Reviewed access
Serious research, licensing, diligence, platform, API, and acquisition routes start with reviewed access.
access requestAdmin reviewcontrolled release
Data-room map
The protected review pack is organised by diligence category.
Reviewers do not need every asset at once. The diligence path should reveal material by buyer need, commercial seriousness, rights scope, and review stage.
Executive buyer summary
High-level narrative for qualified reviewers: what BioAtlas is, what it is not, why it matters, and which protected layers require staged access.
one-page summaryacquisition briefbuyer positioningplatform overview
Asset and product-family map
A structured map of BioAtlas asset families across QTOS, Rubik, oncology, ECS, microbiome, systems biology, cell atlas, neuro, API, and SaaS infrastructure.
review inventorylicence familiesplatform overviewdomain bundles
Research and DOI provenance
Public DOI trail, preprint records, Zenodo records, GitHub timestamped ownership material, and public research pages used for external provenance.
DOI indexZenodo recordspreprintstimestamped ownership
Technical architecture review
Protected review of computational architecture, data boundaries, route families, engine behaviour, QTOS / Rubik positioning, and platform separation.
QTOS architectureRubik layerengine mapprotected app boundary
Commercial packaging review
Licensing pathways, buyer fit, asset-family commercialisation, package scope, rights boundaries, white-label possibilities, and integration routes.
licensing suitebuyer routesAPI accessinstitutional use
Rights, IP and AI-use boundary
Terms for no-AI-ingestion, no derivative database creation, no replication, no scraping, attribution, moral rights, protected use, and negotiated access.
NDAno-AI termsusage boundariesprotected review
Diligence evidence layer
Enzyme intelligence strengthens buyer review
The enzyme layer adds a structured mechanism surface for diligence: systems-state signatures, dataset provenance, evidence summaries, graph-ready relationship context, and protected-depth review pathways.
1,724 enzymes
Atlas
38 groups
Families
6 layers
Field model
Education graph review
A governed reviewer-training graph sits beside the commercial data-room route.
The education graph connects 7 Academy tracks,42 modules, 7 course records, and 10 research families across 92 mapped relationships. It gives reviewers a structured way to understand BioAtlas without exposing raw protected datasets, private route logic, or unrestricted document downloads.
Quiz coverage
42/42
Edges / track
13.14
Safety levels
4
Review pathway
Serious review moves through staged gates.
BioAtlas diligence should protect the asset estate while still giving qualified buyers enough structure to understand scope, strength, provenance, and commercial routes.
01
Public screen
Reviewer reads the public pages, DOI index, licensing overview, safety boundary, and platform positioning without protected vault access.
02
Reviewed access request
Buyer submits a request with role, organisation, intended use, domain interest, and proposed commercial or diligence pathway.
03
Scope triage
BioAtlas separates casual interest from research review, licensing review, investor review, technical diligence, or acquisition conversation.
04
Protected material release
Only relevant material is released: public-safe summaries first, then staged folders, data-room extracts, or controlled demos if appropriate.
05
Rights and terms alignment
AI ingestion, redistribution, derivative use, commercial deployment, exclusivity, territory, API access, and acquisition scope are handled separately.
Buyer fit
The diligence route changes by buyer type.
The commercial audit surfaced buyer signals across professional and clinical reviewers, oncology, research, biotech, pharma, laboratories, enterprises, institutions, investors, acquirers, partners, manufacturers, distributors, institutional routes, and public-health contexts.
strategic acquirerpharma / biotech reviewerresearch institutionenterprise platform buyerprofessional or clinical evaluatorinvestor / diligence leadAPI or SaaS partnerinstitutional / public-health route
A pharma reviewer may need oncology, target, evidence, and integration context. An enterprise buyer may need SaaS, API, workflow, governance, and support context. An acquirer may need platform architecture, IP boundary, valuation, audit, data-room, and provenance material.
Relevant public papers
Diligence provenance trail.
This cross-section gives buyers and reviewers a public proof layer before data-room access: physics-first biology, QTOS, Rubik, oncology, ECS–microbiome integration, adaptive systems, drug resistance, and systems-governance modelling.
Open preprintPhysics-first biology / QTOS
A Physics-First Framework for Multi-Layer Disease Dynamics
Introduces the physics-first disease-dynamics framework across layered collapse, coherence, constraints, and state transitions.
ResearchPhysics-firstPlatformDiligenceLicensing
Read DOI recordZenodo recordQTOS / safety guardrails
QTOS Capability Envelope & System Guardrails (v1.0): Formal Definition of Scope, Limits, and Non-Claims
Defines the QTOS capability envelope, limits, guardrails, non-claims, and infrastructure-grade scope.
ResearchPhysics-firstPlatformSafetyDiligenceLicensing
Read DOI recordZenodo recordRubik / constraint-first computation
Rubik vs Supercomputers: Constraint-First Computation and Governance Infrastructure
Defines Rubik as a constraint-first computation and governance layer below QTOS, focused on reachability, impossibility, and deterministic boundaries.
ResearchPhysics-firstPlatformSafetyDiligenceLicensing
Read DOI recordReportQTOS / platform OS
QTOS Systems-State Framework
Early QTOS record describing the systems-state operating-model concept and platform-level architecture.
ResearchPlatformPhysics-firstDiligenceLicensing
Read DOI recordReportOncology / hallmarks
A Therapeutic Framework Integrating 22 Hallmarks of Cancer with ECS, Bioelectric, and Systems Biology Layers
Maps 22 cancer hallmarks against ECS, signalling, and systems-biology layers for oncology intelligence.
ResearchOncologyDiligenceLicensing
Read DOI recordReportECS / microbiome / systems biology
ECS–Microbiome Integration: A Multi-Domain Systems Biology Framework
Integrates ECS, microbiome, gut-immune-neuro signalling, systems biology, and systems-biology context.
ResearchGut & MicrobiomeSystems BiologyPlatformLicensing
Read DOI recordReportProgrammable OS / neuro / gut-brain-ECS
A Programmable Therapeutic Operating System for Neural, Cognitive, and Gut–Brain–ECS Reprogramming
Defines a programmable operating-system framing for neural, cognitive, gut-brain, and ECS reprogramming research.
ResearchPlatformGut & MicrobiomeSystems BiologyLicensing
Read DOI recordOpen preprintDrug resistance / signalling states
Drug Resistance and Persistent Signalling States: A Compartmental Redistribution Framework
Frames persistent signalling and drug resistance as a compartmental redistribution problem rather than a single-pathway failure.
ResearchOncologyCell AtlasDiligence
Read DOI recordZenodo recordAdaptive systems
Adaptive Biological Systems & State-Based Health Modelling: A Four-Paper Research Series
A four-paper series around state-based health modelling, early instability, biomarker coupling, and human-in-the-loop governance.
ResearchSystems BiologyPlatformDiligence
Read DOI recordZenodo recordGovernance / irreversibility
Causal Sovereignty: Governing Irreversibility in Biological Systems
Frames irreversibility, intervention limits, and biological state governance as a safety and systems problem.
ResearchPhysics-firstSystems BiologySafetyDiligence
Read DOI recordThese records are included for provenance, publication, and review context only. They do not create medical advice, treatment instruction, dosing guidance, autonomous decision-making, or clinical access.
Public diligence map, protected data room
Diligence starts with a public map, then moves into staged release.
The public diligence page shows how the data room is organised. Protected materials are released only by buyer fit, review stage, rights boundary, and commercial seriousness.
Public layer
What can be seen publicly
public page summaries
route map and estate map
DOI and preprint links
research collection names
safe paper summaries
licence family names
buyer lane overview
safety and non-claims boundary
access request funnel
Protected layer
What requires review
protected manuscripts
private vault assets
raw datasets and data-room extracts
buyer packs and valuation notes
pricing and commercial terms
technical architecture detail
internal app surfaces
controlled demos
AI-use or derivative-use rights
Public visibility is not a licence. Public pages do not grant access to protected material, commercial terms, AI ingestion, derivative databases, model training, redistribution, replication, or clinical use.
Protected boundaries
Data-room interest does not grant extraction rights.
Diligence access is staged and permissioned. It does not grant scraping, training, vectorisation, redistribution, replication, derivative databases, commercial deployment, or internal route access.
no public data-room accessno internal route exposureno protected file-path disclosureno AI ingestion by defaultno derivative database rightsno model-training rightsno clinical instructionno prescriptive protocol releaseno admin or internal API linksno acquisition materials without review
Access request
Request the right review lane before deeper material is released.
A useful diligence request should state who is reviewing, which organisation is involved, the intended use, the domains of interest, whether the route is licensing, partnership, investment, acquisition, or technical integration, and whether AI-use rights are being requested.
Request diligence access